US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
US3567725A
(en)
|
1968-11-20 |
1971-03-02 |
Merck & Co Inc |
Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
|
US4294836A
(en)
|
1980-03-24 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
|
US4294837A
(en)
|
1980-03-28 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
|
US4317909A
(en)
|
1980-03-24 |
1982-03-02 |
Sterling Drug Inc. |
Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
|
US4309537A
(en)
|
1980-03-28 |
1982-01-05 |
Sterling Drug Inc. |
Production of imidazo[4,5-b]pyridin-2-ones or thiones
|
GB8709448D0
(en)
|
1987-04-21 |
1987-05-28 |
Pfizer Ltd |
Heterobicyclic quinoline derivatives
|
JPS63275582A
(ja)
|
1987-05-02 |
1988-11-14 |
Naade Kenkyusho:Kk |
2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法
|
DD262026A1
(de)
|
1987-07-10 |
1988-11-16 |
Akad Wissenschaften Ddr |
Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
|
FR2643903A1
(fr)
|
1989-03-03 |
1990-09-07 |
Union Pharma Scient Appl |
Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
|
US4963561A
(en)
|
1990-02-28 |
1990-10-16 |
Sterling Drug Inc. |
Imidazopyridines, their preparation and use
|
TW274550B
(es)
|
1992-09-26 |
1996-04-21 |
Hoechst Ag |
|
DE19601627A1
(de)
|
1996-01-18 |
1997-07-24 |
Bayer Ag |
Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
|
US6031105A
(en)
|
1996-04-09 |
2000-02-29 |
Pfizer Inc |
Substituted pyridines
|
CA2305370C
(en)
|
1997-09-26 |
2006-11-28 |
Gerald Mcmahon |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
CA2311414A1
(en)
|
1997-11-27 |
1999-06-10 |
Chugai Research Institute For Molecular Medicine, Inc. |
Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in lkb1 gene
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
AU4951300A
(en)
|
1999-05-31 |
2000-12-18 |
Chugai Research Institute For Molecular Medicine, Inc. |
Lkb1 gene knockout animals
|
JP2003146987A
(ja)
|
1999-05-31 |
2003-05-21 |
Dainippon Pharmaceut Co Ltd |
2−アリールプリン−9−アセトアミド誘導体
|
JP3814125B2
(ja)
|
1999-06-02 |
2006-08-23 |
大日本住友製薬株式会社 |
2−アリール−8−オキソジヒドロプリン誘導体からなる医薬
|
JP2002100363A
(ja)
|
2000-09-25 |
2002-04-05 |
Mitsubishi Chemicals Corp |
リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
|
JP2002167387A
(ja)
|
2000-11-29 |
2002-06-11 |
Dainippon Pharmaceut Co Ltd |
2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体
|
ATE310004T1
(de)
|
2000-12-12 |
2005-12-15 |
Neurogen Corp |
Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2003020722A1
(de)
|
2001-09-04 |
2003-03-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
|
US6825184B2
(en)
|
2001-10-18 |
2004-11-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-Disubstituted benzo-fused urea compounds
|
MY156407A
(en)
|
2002-02-28 |
2016-02-26 |
Novartis Ag |
5-phenylthiazole derivatives and use as p13 kinase inhibitors
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
AU2003232071A1
(en)
|
2002-05-06 |
2003-11-17 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis c virus infection
|
WO2004042002A2
(en)
|
2002-08-05 |
2004-05-21 |
University Of Massachusetts |
Compounds for modulating rna interference
|
WO2004041285A1
(en)
|
2002-10-31 |
2004-05-21 |
Amgen Inc. |
Antiinflammation agents
|
WO2004048365A1
(en)
|
2002-11-21 |
2004-06-10 |
Chiron Corporation |
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
|
BRPI0406809A
(pt)
|
2003-01-17 |
2005-12-27 |
Warner Lambert Co |
Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
|
CA2517020C
(en)
|
2003-02-26 |
2012-06-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, method for the production and use thereof in the form of drugs
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
PT1633766T
(pt)
|
2003-05-30 |
2019-06-04 |
Gilead Pharmasset Llc |
Análogos de nucleósido fluorado modificado
|
ATE461196T1
(de)
|
2003-06-26 |
2010-04-15 |
Merck Sharp & Dohme |
Benzodiazepin-cgrp-rezeptor-antagonisten
|
ATE392433T1
(de)
|
2003-07-17 |
2008-05-15 |
Univ Dundee |
Verfahren zur anwendung eines an lkb1/strad/mo25- komplexes
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US20080194019A1
(en)
|
2003-09-09 |
2008-08-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
|
US20090186929A1
(en)
*
|
2003-11-10 |
2009-07-23 |
U.S. Department Of Veterans Affairs |
Method and agent for inducing apoptosis/cell death in leukemia cells
|
JP2008501707A
(ja)
|
2004-06-04 |
2008-01-24 |
アイコス、コーポレーション |
マスト細胞障害を処置するための方法
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
WO2006001266A1
(ja)
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
2-アリールプリン誘導体の製造方法
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
JP2008514628A
(ja)
|
2004-09-24 |
2008-05-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
蛋白質キナーゼ類のイミダゾ{4,5−b}ピラジノン阻害剤
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
ES2508766T3
(es)
|
2004-10-29 |
2014-10-16 |
Janssen R&D Ireland |
Derivados de pirimidina bicíclicos que inhiben el VIH
|
WO2006050076A1
(en)
|
2004-10-29 |
2006-05-11 |
Janssen Pharmaceutica, N.V. |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
SE0403006D0
(sv)
|
2004-12-09 |
2004-12-09 |
Biovitrum Ab |
New compounds
|
AU2005316668B2
(en)
|
2004-12-13 |
2012-09-06 |
Millennium Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
PT1853588E
(pt)
|
2005-02-16 |
2008-08-25 |
Astrazeneca Ab |
Compostos químicos
|
WO2006091737A1
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
CA2599320A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
|
WO2006090169A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
|
AU2006232105A1
(en)
|
2005-04-05 |
2006-10-12 |
Pharmacopeia, Inc. |
Purine and imidazopyridine derivatives for immunosuppression
|
EP2322523B1
(en)
|
2005-10-07 |
2019-01-02 |
Exelixis, Inc. |
Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha
|
EA024305B1
(ru)
|
2005-10-07 |
2016-09-30 |
Экселиксис, Инк. |
Ингибиторы фосфатидилинозит-3-киназы и их применение
|
EP1931670B1
(en)
|
2005-10-07 |
2012-09-12 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k
|
EP1946120A2
(en)
|
2005-10-18 |
2008-07-23 |
George Mason Intellectual Properties, Inc. |
Mtor pathway theranostic
|
MY148491A
(en)
|
2005-11-17 |
2013-04-30 |
Osi Pharm Inc |
FUSED BICYCLIC mTOR INHIBITORS
|
JP5161102B2
(ja)
|
2005-11-22 |
2013-03-13 |
クドス ファーマシューティカルズ リミテッド |
mTOR阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
|
GB0525083D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
AU2007204208A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
US20090281075A1
(en)
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
EP2043655A2
(en)
|
2006-04-25 |
2009-04-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
NZ572812A
(en)
|
2006-04-26 |
2010-09-30 |
Hoffmann La Roche |
THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
|
CN101484452A
(zh)
|
2006-05-03 |
2009-07-15 |
阿斯利康(瑞典)有限公司 |
噻唑衍生物及其作为抗肿瘤药物的用途
|
JP2009535388A
(ja)
|
2006-05-03 |
2009-10-01 |
アストラゼネカ アクチボラグ |
ピラゾール誘導体、及びそのpi3k阻害薬としての使用
|
JP2009537621A
(ja)
|
2006-05-22 |
2009-10-29 |
アストラゼネカ アクチボラグ |
インドール誘導体
|
RS54542B1
(en)
|
2006-08-02 |
2016-06-30 |
Cytokinetics, Inc. |
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE
|
JP5227321B2
(ja)
|
2006-08-23 |
2013-07-03 |
クドス ファーマシューティカルズ リミテッド |
Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
|
US20100144738A1
(en)
|
2006-09-05 |
2010-06-10 |
William Bornmann |
Inhibitors of c-met and uses thereof
|
JP5600004B2
(ja)
|
2006-09-05 |
2014-10-01 |
エモリー ユニバーシティー |
感染の予防または治療のためのチロシンキナーゼ阻害剤
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
CN101563339A
(zh)
|
2006-09-14 |
2009-10-21 |
阿斯利康(瑞典)有限公司 |
作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
US20090270390A1
(en)
|
2006-09-14 |
2009-10-29 |
Astrazeneca |
Pyrimidine derivatives
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
US20090233926A1
(en)
|
2006-09-14 |
2009-09-17 |
Astrazeneca |
2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
TW200831104A
(en)
|
2006-10-04 |
2008-08-01 |
Pharmacopeia Inc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
AU2007309468B2
(en)
|
2006-10-19 |
2012-05-17 |
Signal Pharmaceuticals, Llc |
Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
|
ATE543819T1
(de)
|
2006-10-19 |
2012-02-15 |
Signal Pharm Llc |
Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
|
EP2094700B1
(en)
|
2006-11-20 |
2014-04-02 |
Novartis AG |
Crystalline monotosylate salt of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
US8263329B2
(en)
*
|
2007-03-29 |
2012-09-11 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
KR20100042643A
(ko)
|
2007-07-09 |
2010-04-26 |
아스트라제네카 아베 |
증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체
|
JP2010533158A
(ja)
|
2007-07-09 |
2010-10-21 |
アストラゼネカ アクチボラグ |
化合物類−945
|
US8138183B2
(en)
|
2007-07-09 |
2012-03-20 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
|
KR20100083170A
(ko)
|
2007-10-16 |
2010-07-21 |
와이어쓰 엘엘씨 |
티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 mTOR 키나제 및 PI3 키나제 억제제로서의 용도
|
EP2219646A4
(en)
|
2007-12-21 |
2010-12-22 |
Univ Rochester |
METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
|
JP2011510010A
(ja)
|
2008-01-15 |
2011-03-31 |
ワイス・エルエルシー |
3H−[1,2,3]トリアゾロ[4,5−d]ピリミジン化合物、mTORキナーゼおよびPI3キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
|
WO2009102986A1
(en)
|
2008-02-15 |
2009-08-20 |
Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) |
Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
CA2744498C
(en)
|
2008-11-25 |
2017-10-24 |
University Of Rochester |
Mlk inhibitors and methods of use
|
US20100297194A1
(en)
*
|
2009-04-30 |
2010-11-25 |
Nathaniel Catron |
Formulation for oral administration of apoptosis promoter
|
PL2477987T3
(pl)
|
2009-09-14 |
2018-06-29 |
Gilead Sciences, Inc. |
Modulatory receptorów toll-podobnych
|
MX341704B
(es)
*
|
2009-10-26 |
2016-08-31 |
Signal Pharm Llc |
Métodos de síntesis y purificación de compuestos de heteroarilo.
|
EP2516441B1
(en)
|
2009-12-23 |
2015-01-21 |
Elan Pharmaceuticals Inc. |
Pteridinones as inhibitors of polo-like kinase
|
NZ601581A
(en)
|
2010-02-03 |
2014-03-28 |
Signal Pharm Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
US20110318336A1
(en)
|
2010-03-29 |
2011-12-29 |
George Mason Intellectual Properties, Inc. |
Identification and Treatment of Aggressive Lung Cancer Tumors
|
US20120028972A1
(en)
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
US20120238562A1
(en)
*
|
2011-03-09 |
2012-09-20 |
Cedars-Sinai Medical Center |
Treatment of cancer by targeting molecules that influence mst1/stk4 signaling
|
MX2014001246A
(es)
|
2011-08-03 |
2014-06-11 |
Signal Pharm Llc |
Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
|
CN103998036B
(zh)
|
2011-10-19 |
2017-05-31 |
西格诺药品有限公司 |
利用tor激酶抑制剂治疗癌症
|
CA2857155C
(en)
|
2011-12-02 |
2021-09-21 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
JP6114317B2
(ja)
|
2012-02-24 |
2017-04-12 |
シグナル ファーマシューティカルズ,エルエルシー |
Torキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
|
NZ628420A
(en)
|
2012-03-15 |
2016-04-29 |
Signal Pharm Llc |
Treatment of cancer with tor kinase inhibitors
|
SG11201405707XA
(en)
|
2012-03-15 |
2014-10-30 |
Signal Pharm Llc |
Treatment of cancer with tor kinase inhibitors
|
TWI664968B
(zh)
|
2012-03-15 |
2019-07-11 |
標誌製藥公司 |
使用tor激酶抑制劑之癌症治療
|
NZ628407A
(en)
|
2012-03-15 |
2016-04-29 |
Signal Pharm Llc |
Treatment of cancer with tor kinase inhibitors
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
WO2014172436A1
(en)
*
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
CN105324381A
(zh)
*
|
2013-04-17 |
2016-02-10 |
西格诺药品有限公司 |
有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
|
CA2908353C
(en)
|
2013-04-17 |
2021-11-02 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
TW201526894A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
藉二氫吡并吡治療癌症
|
NZ631082A
(en)
|
2013-04-17 |
2017-06-30 |
Signal Pharm Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
UA115805C2
(uk)
|
2013-04-17 |
2017-12-26 |
Сігнал Фармасьютікалз, Елелсі |
Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
|
TW201526897A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
US9505764B2
(en)
|
2013-04-17 |
2016-11-29 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
AU2014254057A1
(en)
|
2013-04-17 |
2015-11-05 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
EP3131552B1
(en)
*
|
2014-04-16 |
2020-07-15 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
JP2017511367A
(ja)
*
|
2014-04-16 |
2017-04-20 |
シグナル ファーマシューティカルズ,エルエルシー |
1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法
|
NZ714742A
(en)
*
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|